Imperial College London
Professor Dragana Milojkovic

ProfessorDraganaMilojkovic

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Practice (Chronic Myeloid Malignancies)
 
 
 
//

Contact

 

+44 (0)20 3313 1627d.milojkovic

 
 
//

Location

 

Cancer CentreHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cook:2022,
author = {Cook, L and O'dell, G and Vourvou, E and Palanicawandar, R and Marks, S and Milojkovic, D and Apperley, J and Loaiza, S and Claudiani, S and Bua, M and Hockings, C and Macdonald, D and Chaidos, A and Pavlu, J and Cooper, N and Fidler, S and Randell, P and Innes, A},
journal = {Nature Communications},
pages = {1--6},
title = {Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies},
url = {https://www.nature.com/articles/s41467-022-34657-z},
volume = {13},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - SARS-CoV-2 infection, and resulting disease, COVID-19, has a high mortality amongst patients with haematological malignancies. Global vaccine rollouts have reduced hospitalisations and deaths, but vaccine efficacy in patients with haematological malignancies is known to be reduced. The UK-strategyoffered a third, mRNA-based, vaccine as an extension to the primary course in these patients. The MARCH database is a retrospective observational study of serological responses in patients with blood disorders. Here we present data on 381 patients with haematological malignancies. By comparison with healthy controls, we report suboptimal responses following two primary vaccines, with significantly enhanced responses following the third primary dose. These responses however are heterogeneous and determined by haematological malignancy sub-type and therapy. We identify a group of patients with continued sub-optimal vaccine responses who may benefit from additional doses, prophylactic extended half-life neutralising monoclonal therapies (nMAB) or prompt nMAB treatment in the event of SARS-CoV-2 infection.
AU  - Cook,L
AU  - O'dell,G
AU  - Vourvou,E
AU  - Palanicawandar,R
AU  - Marks,S
AU  - Milojkovic,D
AU  - Apperley,J
AU  - Loaiza,S
AU  - Claudiani,S
AU  - Bua,M
AU  - Hockings,C
AU  - Macdonald,D
AU  - Chaidos,A
AU  - Pavlu,J
AU  - Cooper,N
AU  - Fidler,S
AU  - Randell,P
AU  - Innes,A
EP  - 6
PY  - 2022///
SN  - 2041-1723
SP  - 1
TI  - Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
T2  - Nature Communications
UR  - https://www.nature.com/articles/s41467-022-34657-z
UR  - http://hdl.handle.net/10044/1/100319
VL  - 13
ER  -
Download